Business
Assertio is a pharmaceutical company with commercial capabilities and a portfolio led by ROLVEDON, INDOCIN products, Sympazan, SPRIX Nasal Spray, and royalty revenue.
Assertio revenue fell 5.0% to $118.7M, net loss widened to $30.4M, and cash from ops swung to -$28.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Commercial pharmaceutical portfolioNote
- Revenue — Revenue fell 5.0%Watch
- Losses — Net loss widened 40.7%Watch
- Cash — Cash from ops -$28.2MWatch
- Balance sheet — Equity fell 22.4%Watch
- Insiders — 0 buys / 1 sellWatch
- Accounting — Altman-Z distress; Beneish flagWatch
Where the revenue comes from
Fiscal 2025, as Assertio Holdings, Inc. reports it. History and quarterly detail are in the app.
- Product sales, net$117.1M
- Royalty revenue$1.6M
Leadership changes
From Assertio Holdings, Inc.'s own filings, the day they're filed.
- Mark Reisenauer · Chief Executive Officer · appointmenteff. 2025-10-27
- Brendan O'Grady · Chief Executive Officer · departureeff. 2025-10-27
- Mark Reisenauer · Directors · appointmenteff. 2025-01-02
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-05-13
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Assertio Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.